Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875966 | 0.90 | CYP2C9 (0.37) | MEN1CYP2C9KMT2AALDH1A1OPRM1 | |
| SCHEMBL14260462 | 0.86 | OPRM1 (0.49) | KMT2AALDH1A1OPRM1OPRK1OPRL1 | |
| SCHEMBL14531844 | 0.81 | PDE4B (0.48) | MEN1KMT2AALDH1A1MAOASMN1; SMN2 | |
| SCHEMBL14260464 | 0.81 | PDE4B (0.48) | MEN1KMT2AALDH1A1MAOASMN1; SMN2 | |
| SCHEMBL5876222 | 0.81 | DAO (0.35) | MEN1KMT2AHSD11B1MAOAMAOB | |
| SCHEMBL8992285 | 0.79 | CYP2C9 (0.38) | MEN1CYP2C9KMT2AALDH1A1AKR1C1 | |
| SCHEMBL9729483 | 0.79 | HDAC4 (0.40) | OPRM1OPRK1OPRL1HSD11B1 | |
| SCHEMBL9729634 | 0.79 | KDM1A (0.40) | OPRM1OPRK1OPRL1HSD11B1 | |
| SCHEMBL9729263 | 0.79 | SLC6A4 (0.40) | MEN1KMT2AHSD11B1 | |
| SCHEMBL8873535 | 0.77 | MEN1 (0.41) | MEN1CYP2C9KMT2AALDH1A1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106562-B2 | Process for manufacture of gadofosveset trisodium monohydrate | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-10-23 | — | — | US | claimed |
| US-20160016979-A1 | PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE | CITIZENS BANK, N.A. | 2016-01-21 | — | — | US | claimed |
| EP-2970140-A1 | PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE | Lantheus Medical Imaging, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160039-A1 | PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| EP-3137440-B1 | BONDING AGENTS FOR NITROGEN-CONTAINING OXIDIZERS | RAYTHEON CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10227267-B2 | Bonding agents for nitrogen-containing oxidizers | RAYTHEON COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10106562-B2 | Process for manufacture of gadofosveset trisodium monohydrate | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3137438-B1 | METHODS TO DESENSITIZE HYDRAZINIUM NITROFORMATE (HNF) | RAYTHEON CO (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-22 | — | — | US | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997046511-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5508433-A | Derivatives of perhydroisoindole and preparation thereof | RHONE-POULENC RORER S.A. (FR) | 1996-04-16 | — | — | US | disclosed |
| US-5451601-A | Perhydroisoindole derivatives and pharmaceutical compositions containing them | RHONE-POULENC RORER S.A. (FR) | 1995-09-19 | — | — | US | disclosed |
| US-5112988-A | ISOINDOLONE DERIVATIVES | RHONE-POULENC SANTE (FR) | 1992-05-12 | — | — | US | disclosed |
| US-5102667-A | Antiallergens, antiinflammatory agents, nervous system disorders, immunology, psychological disorders | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016979-A1 | PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE | SLC6A13, SLC6A11, MPST | MEN1 268/4885CYP2C9 1176/4885KMT2A 2904/4885 |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | CFB, C3AR1, C9 | MEN1 204/4885CYP2C9 4213/4885KMT2A 4462/4885 |
| US-10106562-B2 | Process for manufacture of gadofosveset trisodium monohydrate | SLC6A13, SLC6A11, MPST | MEN1 268/4885CYP2C9 1176/4885KMT2A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.